CRISPR, Vertex partner in $3.6bn CRISPR-Cas9 gene editing collaboration; later expanded to other disease areas
CRISPR Therapeutics is lending its CRISPR-Cas9 gene editing technology to Vertex Pharmaceuticals Inc. as part of a four-year research collaboration aimed at discovering treatments to address the underlying genetic defects that cause or contribute to certain diseases, including cystic fibrosis and sickle cell disease.
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Technologies
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.